护城河对比

Narrow rather than wide because the FY2026 10-K argues both ways and its own risk factors are the harder side: it describes a self-reinforcing data advantage and says "we do not believe any of our competitors currently have a true platform offering equivalent to the Falcon platform", but the same filing calls the market for security and IT operations solutions "intensely competitive, fragmented", warns that "Competitive pricing pressure may reduce our gross profits", and still carries the July 19 Incident as having "had, and is expected to continue to have, an adverse effect on our business, sales, customer and partner relations, reputation" more than two years after it occurred.

来源：sec.gov

The FY2025 10-K asserts a durable competitive position across essentially all of the revenue base: for Electrical Americas and Electrical Global it states 'Eaton has a strong competitive position in these segments and, with respect to many products, is considered among the market leaders'; it repeats that language verbatim for Aerospace ('industry-leading portfolio', 'considered among the market leaders'); and for Vehicle it states 'Eaton is considered among the market leaders in this segment.' That is a claimed leadership position in four of the five reported segments, on a base of $27.4 billion of 2025 revenue, ~97,000 employees and customers in 180 countries, from a company founded in 1911. The rating is tempered rather than lifted higher by the filing's own admissions - price is named among the principal methods of competition in the Electrical, Vehicle and eMobility segments, and the risk factors flag 'newly competitive market players' and that 'our positions may also be impacted by new entrants into our product or regional markets.'

来源：sec.gov

The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion.

来源：sec.gov

The 10-K states the mechanism directly: "The more data that is fed into our Falcon platform, the more intelligent the AI Security Cloud becomes, the stronger our ability to anticipate and counter evolving adversary tradecraft, and the more our customers benefit, creating a powerful network effect that increases the overall value we provide."

来源：sec.gov

The filing's own description of how it competes points at designed-in and qualified positions rather than IP or pure scale. In Aerospace the principal methods of competition are listed as 'total cost of ownership, product and system performance, quality, design engineering capabilities, and timely delivery' - price is conspicuously absent, and 20% of segment sales go to three large aircraft OEMs, i.e. platform-level content that is qualified in and hard to displace mid-programme. In the Electrical segments 'customer service and support' sits alongside performance and technology as a method of competition, and 22% of sales go to six large customers. Intangibles_ip is explicitly ruled out as the primary source by the company itself: 'management believes that the loss or expiration of any single intellectual property right would not in and of itself have a material effect on Eaton's consolidated financial statements or its business segments.' Scale is real but secondary - the filing notes raw materials are bought 'from many suppliers' and 'under normal circumstances, the Company has no difficulty obtaining its raw materials,' which reads as supply resilience rather than a cost advantage claim.

来源：sec.gov

The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power."

来源：sec.gov

Co-leader rather than clear leader because the only claim of platform primacy available is the company's own ("we do not believe any of our competitors currently have a true platform offering equivalent"), while the same 10-K describes a fragmented market and lists seven distinct categories of competitor, from legacy antivirus to network security, cloud security, identity and legacy SIEM vendors.

来源：sec.gov

The filing's leadership language is plural and hedged, not exclusive: 'considered among the market leaders' for the Electrical segments (qualified further by 'with respect to many products'), 'among the market leaders' for Aerospace, and 'Eaton is considered among the market leaders' for Vehicle. Nowhere does the 10-K claim to be the single leader in any market, and it never names a competitor or cites a market-share figure. 'Among the market leaders' maps to co_leader, not clear_leader.

来源：sec.gov

The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date."

来源：sec.gov

The 10-K's risk factors state that "Competitive pricing pressure may reduce our gross profits" and that competing successfully may require "aggressive pricing", which is the company's own case against strong pricing power; the offsetting factor it cites is module consolidation on one sensor.

来源：sec.gov

The filing describes pass-through ability that is real but bounded. On input costs: 'While we strive to recoup these increased costs through our pricing, product modifications or other mediating responses, if we are unable to do so without compromising the competitive position of our products and services, our results could continue to be impacted by this trend.' On macro conditions: 'our responses to mitigate the impact of these conditions, such as potential price increases, could negatively impact our market share or relationships with distributors or customers.' On tariffs: 'potential price increases or other mitigating efforts could negatively impact market share or otherwise increase the risk of customer disputes.' Price is also listed as a principal method of competition in Electrical Americas, Electrical Global, Vehicle and eMobility - so raising price is described by the company as costing share. Aerospace is the exception, where price is not among the listed methods of competition. The filing states no gross-margin trend in Item 1 or Item 1A.

来源：sec.gov

Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries."

来源：sec.gov

AI-native security platform — an adopter and reseller of AI rather than a supplier of AI infrastructure.

Upstream electrical infrastructure into AI compute: Eaton supplies the power path from grid to rack, and the 10-K makes that link itself - data center is the first market it names, it cites 'momentum in the data center and utility end markets,' and its 2025-26 acquisitions target hyperscale/colocation modular buildings, solid-state transformers and liquid cooling 'from the chip to the grid.' Its exposure to AI is as a supplier to AI buildout, not as an AI technology vendor; the filing's only AI discussion of its own products is a risk factor about keeping pace with AI internally and about generative-AI compliance risk, which is incidental to the thesis.

A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish.

• Charlotte AI 未知 · 中等 来源：sec.gov
• Falcon endpoint & cloud workload security 未知 · 深 来源：sec.gov
• Falcon identity protection 未知 · 中等 来源：sec.gov
• Next-Gen SIEM and log management 未知 · 中等 来源：sec.gov
• Threat intelligence and professional services 未知 · 低 来源：sec.gov

• Aerospace 前三 · 深 来源：sec.gov
• Electrical Americas 前三 · 中等 来源：sec.gov
• Electrical Global 前三 · 中等 来源：sec.gov
• Vehicle 前三 · 中等 来源：sec.gov
• eMobility 未知 · 低 来源：sec.gov

• Intismeran autogene (mRNA-4157) 未知 · 中等 来源：sec.gov
• Spikevax 前三 · 中等 来源：sec.gov
• mNEXSPIKE 前三 · 中等 来源：sec.gov
• mRESVIA 挑战者 · 中等 来源：sec.gov
• mRNA-1010 seasonal influenza vaccine 未知 · 中等 来源：sec.gov

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →